Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

Leukemia

Volumn 28, Issue 8, 2014, Pages 1754-1758

  Becker, H ^a,j   Maharry, K ^a,b   Mrozek K ^a   Volinia, S ^a   Eisfeld, A K ^a   Radmacher, M D ^a   Kohlschmidt, J ^a,b   Metzeler, K H ^a   Schwind, S ^a   Whitman, S P ^a   Mendler, J H ^a   Wu, Y Z ^a   Nicolet, D ^a   Paschka, P ^a   Powell, B L ^c   Carter, T H ^d   Wetzler, M ^e   Kolitz, J E ^f   Carroll, A J ^g   Baer, M R ^h   Caligiuri, M A ^a   Stone, R M ⁱ   Marcucci, G ^a   Bloomfield, C D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f North Shore Long Island Center for Advanced Medicine   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 8; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TRISOMY;

EID: 84905695377     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.114     Document Type: Letter

References (17)

1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010; 10: 401.
4. Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, Knudson RA et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia [letter]. Leukemia 2010; 24: 2120-2122.
5. Alpermann T, Haferlach C, Eder C, Kohlmann A, Kern W, Haferlach T et al. Sole trisomy 8 in AML: concomitant molecular markers, stability of genetic patterns and impact on outcome. Blood 2012; 120: (abstract 2503).
6. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98: 1124-1129.
7. Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T. Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer 2006; 45: 1164-1168.
8. Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
9. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418-1425.
10. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308-1316.
11. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 5660-5669.
12. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348-2355.
13. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, Guimond M et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 2004; 101: 3915-3920.
14. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305: 59-67.
15. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 6334-6339.
16. Garcí a-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ et al. Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia. PLoS One 2012; 7: e47717.
17. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148-4157.